Immuno-Oncology | Specialty

Nivolumab Demonstrates Broad Efficacy in NSCLC

November 7th 2015

The latest FDA approval for nivolumab in non–small cell lung cancer means that the drug potentially can be administered to any patient in the second-line setting, regardless of tumor histology or PD-L1 expression level.

Checkpoint Inhibitors Show Promise in SCLC, Mesothelioma

November 7th 2015

Immune checkpoint inhibitors have demonstrated encouraging results for patients with small cell lung cancer and mesothelioma, which are two aggressive thoracic malignancies with few options.

Dr. Howard L. Kaufman on Impact of T-VEC FDA Approval

November 6th 2015

Howard L. Kaufman, MD, FACS, Chief Surgical Officer, Associate Director for Clinical Science, Surgical Oncologist, Rutgers Cancer Institute, Society for Immunotherapy of Cancer (SITC) President, discusses the impact of the recent FDA approval of talimogene laherparepvec (T-VEC) for the treatment of melanoma lesions in the skin and lymph nodes.

Willem Overwijk Explains the Role of the Innate Immune System in Cancer Treatment

November 6th 2015

Willem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.

Dr. Stephen Grupp on Engineered Cell Therapy for the Treatment of Pediatric ALL

November 5th 2015

Stephen Grupp, MD, PhD, director of translational research for the center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses the use of engineered cell therapy for the treatment of Acute Lymphoblastic Leukemia (ALL).

Immunotherapy Not Ready for Prime Time in Ovarian Cancer

November 5th 2015

Early promising responses seen with immune checkpoint inhibitors for patients with ovarian cancer still need to be validated in larger randomized trials before a conclusion is made regarding their true efficacy.

Atezolizumab Shows Promise of PD-1/PD-L1 Blockade in Metastatic Bladder Cancer

November 4th 2015

Immune checkpoint blockade has transformed the treatment paradigms of multiple advanced solid tumors-and bladder cancer is no exception.

Dr. Toni Choueiri on Cabozantinib and Nivolumab Combination in Kidney Cancer

November 3rd 2015

Toni Choueiri, MD, Dana-Farber Cancer, Clinical Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Dana Farber Cancer, discusses the potential for combination treatments in kidney cancer.

Marianne Davies on Managing Immunotherapy Side Effects in Lung Cancer

November 2nd 2015

Marianne Davies, NP, Assistant Professor of and Clinical Instructor in Nursing, Yale Cancer Center, discusses immune-mediated adverse events in lung cancer.

Pembrolizumab Granted Breakthrough Status for Microsatellite Instability-High mCRC

November 2nd 2015

The FDA has granted a breakthrough therapy designation to pembrolizumab as a potential therapy for patients with microsatellite instability-high metastatic colorectal cancer.

Motzer Discusses Nivolumab's Survival, QoL Benefits in RCC

November 2nd 2015

Robert J. Motzer, MD, discusses nivolumab's impact for renal cell carcinoma treatment.

Expert Discusses Future of Immunotherapy in Lung Cancer

October 30th 2015

Heather Wakelee, MD, reflected on the evolution of lung cancer treatment and just how significant of an impact immunotherapies may have.

Petrylak Highlights Potential of PD-1/PD-L1 Inhibitors in Bladder Cancer

October 29th 2015

PD-1/PD-L1 agents have shown significant potential for the treatment of urothelial bladder cancer, Daniel Petrylak, MD, from Yale Cancer Center, noted in a recent interview with OncLive.

PD-1 Immunotherapy Combos May Be Next Step in Hodgkin Lymphoma Therapy

October 29th 2015

The prospect of combining PD-1 inhibitors with existing therapies, particularly brentuximab vedotin, is emerging as the most exciting new development in advancing the treatment of patients with Hodgkin lymphoma, raising the possibility of improving the cure rates in a disease where standard strategies have already produced notable results.

FDA Approves Adjuvant Ipilimumab in Melanoma

October 28th 2015

The FDA expanded the approval of ipilimumab (Yervoy) in melanoma to include adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.

FDA Approves T-VEC for Advanced Melanoma

October 27th 2015

The FDA has approved talimogene laherparepvec for the treatment of patients with advanced melanoma.

Pembrolizumab Improves Survival Versus Docetaxel in PD-L1+ NSCLC

October 26th 2015

Pembrolizumab (Keytruda) extended overall survival versus docetaxel in the phase II/III KEYNOTE-010 trial.

Enhanced Immune Response Seen With Radiation/Ipilimumab Combo in Melanoma

October 24th 2015

Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti–CTLA-4 immunotherapy, ipilimumab.

Mayo Study Characterizes Pembrolizumab-Induced Thyroiditis

October 23rd 2015

Abnormal thyroid function tests were reported in up to 15% of patients treated with the PD-1 inhibitor pembrolizumab.

CHMP Recommends T-VEC Approval for Melanoma

October 23rd 2015

Talimogene laherparepvec has received a positive recommendation from the CHMP, which suggests that the treatment should gain European approval for patients with advanced melanoma.

NEXT PAGE
PREVIOUS PAGE